^Homesley HD, Hahne WF, McLees B, et al. Randomized comparison of the antiemetic efficacy of a serotonin type 3 receptor antagonist (MDL 72,222) with a high-dose metoclopramide regimen. Am. J. Clin. Oncol. April 1993, 16 (2): 175–9. PMID 8452114. S2CID 11733418. doi:10.1097/00000421-199304000-00020.
^McKinzie DL, McBride WJ, Murphy JM, Lumeng L, Li TK. Effects of MDL 72222, a serotonin3 antagonist, on operant responding for ethanol by alcohol-preferring P rats. Alcohol. Clin. Exp. Res. October 2000, 24 (10): 1500–4. PMID 11045857. doi:10.1111/j.1530-0277.2000.tb04567.x.
^Kos T, Popik P, Pietraszek M, et al. Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol. May 2006, 16 (4): 297–310. PMID 16288851. S2CID 43575963. doi:10.1016/j.euroneuro.2005.10.001.
^Yoo JH, Nam YS, Lee SY, Jang CG. Dopamine neurotransmission is involved in the attenuating effects of 5-HT3 receptor antagonist MDL 72222 on acute methamphetamine-induced locomotor hyperactivity in mice. Synapse. January 2008, 62 (1): 8–13. PMID 17948891. S2CID 20699645. doi:10.1002/syn.20461.